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vestigated the impact of the intestinal flora on disease sever-
ity by performing cohousing experiments of wild-type and 
Nlrp3 –/– mice, as well as by antibiotic treatment.  Results: 
Nlrp3 –/– mice treated with either DSS or TNBS exhibited at-
tenuated colitis and lower mortality. This protective effect 
correlated with an increased frequency of CD103+ lamina 
propria dendritic cells expressing a tolerogenic phenotype 
in Nlrp3 –/– mice in steady state conditions. Interestingly, after 
cohousing, Nlrp3 –/– mice were as susceptible as wild-type 
mice, indicating that transmission of endogenous bacterial 
flora between the two mouse strains might increase suscep-
tibility of Nlrp3 –/– mice towards DSS-induced colitis. Accord-
ingly, treatment with antibiotics almost completely prevent-
ed colitis in the DSS model.  Conclusions: The composition 
of the intestinal microflora significantly influences disease 
severity in IBD models comparing wild-type and Nlrp3 –/– 
mice. This observation may – at least in part – explain con-
tradictory results concerning the role of the inflammasome 
in different labs. Further studies are required to define the 
role of the Nlrp3 inflammasome in noninflamed mucosa un-
der steady state conditions and in IBD. 
 Copyright © 2012 S. Karger AG, Basel 
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 Abstract 
 Background: Inflammatory bowel disease (IBD) is character-
ized by chronic intestinal inflammation due to dysregulation 
of the mucosal immune system. The cytokines IL-1  and IL-18 
appear early in intestinal inflammation and their pro-forms 
are processed via the caspase-1-activating multiprotein 
complex, the Nlrp3 inflammasome. Previously, we reported 
that the uptake of dextran sodium sulfate (DSS) by macro-
phages activates the Nlrp3 inflammasome and that Nlrp3 –/– 
mice are protected in the acute DSS colitis model. Of note, 
other groups have reported opposing effects in regards to 
DSS susceptibility in Nlrp3 –/– mice. Recently, mice lacking
inflammasomes were found to develop a distinct intestinal 
microflora.  Methods: To reconcile the contradicting obser-
vations, we investigated the role of Nlrp3 deficiency in two 
different IBD models: acute DSS colitis and TNBS (2,4,6-trini-
trobenzene sulfonic acid)-induced colitis. In addition, we in-
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 Introduction 
 Crohn’s disease and ulcerative colitis are inflamma-
tory bowel diseases (IBD) with a chronic, relapsing, and 
remitting course  [1] . The etiology of IBD is incompletely 
understood. Both genetic and environmental factors me-
diate the dysregulation of the mucosal immune system in 
the gastrointestinal tract. Even in healthy conditions, 
small amounts of bacterial antigen can cross the epithe-
lial barrier that separates the gut lumen from the adjacent 
mucosa and submucosa. These bacteria or their constitu-
ents interact with various immune cells, in particular 
macrophages and dendritic cells (DC) in the lamina pro-
pria. The constant challenge of the mucosal immune sys-
tem has led to evolutionarily conserved feedback mecha-
nisms protecting the organism from excessive immune 
responses. Under healthy conditions, these feedback 
mechanisms create an equilibrium that is known as the 
mucosal steady state  [2] . Danger signals are believed to 
break this steady state and initiate proinflammatory cas-
cades  [3] . Immune responses to such signals must differ-
entiate between the ‘harmless’ normal intestinal flora 
and more pathogenic bacteria that need to be ‘defeated’. 
However, even under the conditions of active inflamma-
tion, the feedback loops of a healthy organism are pre-
served and effectively limit the proinflammatory im-
mune response within the lamina propria. There is ample 
evidence that mutations in defined components of im-
mune signaling cascades predispose to the development 
of IBD. Dozens of molecular candidates have been identi-
fied that contribute to a deregulated phenotype  [4, 5] .
 However, it is currently unknown if these deregulat-
ed molecular cascades exert their proinflammatory ef-
fects in the absence of specific environmental factors
or if an initial pathogenic stimulus is needed to initiate 
the detrimental cascade, eventually leading to IBD. Re-
cently, it was demonstrated that norovirus infection of
ATG16L1-deficient mice triggers intestinal inflamma-
tion. Genetic factors (ATG16L1), environmental factors 
(the commensal flora), and danger signals (dextran so-
dium sulfate (DSS), norovirus infection) were shown to 
act in concert in order to induce manifest intestinal in-
flammation. Anti-TNF-  and anti-IFN-  strategies, as 
well as antibiotic treatment, were able to ameliorate coli-
tis induction  [6] .
 Possibly, shifts in the genetic signature of individuals 
may exert an influence on the environmental factors 
themselves (composition of the intestinal bacteria set-
tling in the host from the first days of life – long before 
disease appears)  [7] . Of interest, all these mechanisms pu-
tatively affect the interpretation of data of pharmacolog-
ical intervention studies as well as of gene knockout stud-
ies in the field of IBD.
 Materials and Methods 
 Mice  
 Nlrp3 –/– mice were bred at the University of Munich and used 
for experiments at ages spanning 8–16 weeks. Age-matched wild-
type controls were purchased from Harlan Laboratories (Bor-
chen, Germany). Mice were fed standard mice chow pellets and 
had access to tap water supplied in bottles. All experiments were 
approved by the regional animal study committee and are in 
agreement with the guidelines for the proper use of animals in 
biomedical research.
 Induction of Colitis and Treatment 
 DSS colitis was induced with 2% DSS (MW 40 kDa) dissolved 
in drinking water given ad libitum. Control mice were given tap 
water. To investigate the influence of intestinal flora on the extent 
of the colitis, Nlrp3 –/– mice and wild-type controls were cohoused 
in order to assure transfer of intestinal microbiota. Both mouse 
strains were kept together in cages for 2 weeks before DSS expo-
sure. In addition, treatment with a combination of antibiotics was 
investigated. Mice received drinking water with or without ampi-
cillin (1 mg/ml), metronidazole (1 mg/ml), neomycin (1 mg/ml), 
and vancomycin (0.5 mg/ml). TNBS (2,4,6-trinitrobenzene sul-
fonic acid) colitis was induced by rectal administration of 2 doses 
of 2 mg TNBS (Sigma, St. Louis, Mo., USA) in 40% ethanol, using 
a vinyl catheter with the opening position 2.5 cm away from the 
anus. Administration of the two doses was separated by a 7-day 
interval. Mice were sacrificed on day 9 for histological analysis.
 Clinical Score and Histological Analysis 
 A scoring system was used in order to assess diarrhea and the 
presence of occult or overt blood in the stool. Postmortem, the 
colon was removed and pieces of colonic tissue were used for his-
tological analysis. Rings of the transverse part of the colon were 
fixed in 4% buffered formalin, embedded in paraffin, and stained 
with hematoxylin and eosin. Histological scoring was performed 
in a blinded way by a pathologist (H.-A.L.) as described  [8] .
 Ex vivo Analysis of Lamina Propria CD103+ DC 
 For isolation of immune cells from the lamina propria, colon 
sections were cut into small fragments, incubated with EDTA 
(Sigma-Aldrich, Munich, Germany) and dithiothreitol (Sigma-
Aldrich) in Hanks’ balanced salt solution, and passed through a 
70-  m cell strainer. The suspension of epithelial and subepithe-
lial cells as well as intraepithelial lymphocytes was removed and 
the remaining lamina propria was collected. After digestion with 
collagenase D, DNase I, and dispase (Roche, Mannheim, Germa-
ny) the suspension was stained with fluorochrome-labeled anti-
bodies against CD11b, CD11c, CD86 (BD Biosciences, Heidelberg, 
Germany), and CD103 (BioLegend, San Diego, Calif., USA). Fluo-
rescence intensity was analyzed using a FACSCalibur (BD Biosci-
ences, San Diego, Calif., USA). Data analysis was performed using 
FlowJo software (Tree Star, Ashland, Oreg., USA). 
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 Statistics 
 Data are expressed as means  8 SEM. Statistical significance 
of differences between treatment and control groups was deter-
mined by Student’s t test. Differences were considered statisti-
cally significant at p  ! 0.05.
 Results and Discussion 
 Role of the Nlrp3 Inflammasome in IBD 
 Recently, Nlrp3 has emerged as an important player in 
the field of inflammatory response. Activation of cas-
pase-1 was found to be controlled by a cytosolic multipro-
tein complex termed the inflammasome  [9] . Since the 
original description in 2002, several inflammasome com-
plexes have been described, which differ in their subdo-
mains, including Nlrp1, Nlrp3, Nlrc4, and Aim2. Where-
as Nlrp1, Nlrc4, and Aim2 are thought to be primarily 
involved in recognition of microbial products, the Nlrp3 
inflammasome also induces inflammatory responses to-
wards certain sterile stimuli  [10] . Diseases such as gout, 
asbestosis, diabetes, and atherosclerosis are mediated by 
the Nlrp3 inflammasome  [11–13] . The Nlrp3 inflamma-
some is a multimeric complex consisting of Nlrp3, the 
adaptor molecule apoptosis-associated speck-like protein 
(ASC), and procaspase-1. Upon Nlrp3 stimulation, ASC 
and procaspase-1 are recruited to form a large complex 
with subsequent autocleavage of procaspase-1. Active cas-
pase-1 cleaves pro-IL-1  and pro-IL-18 into their biologi-
cally active forms, which are then secreted into the extra-
cellular space. This process involves two distinct steps: (1) 
transcriptional upregulation of Nlrp3 and pro-IL-1  /IL-
18 via NF-  B or cytokine receptor signaling, and (2) acti-
vation of the Nlrp3 inflammasome  [14] .
 Several reports have established an association be-
tween the inflammasome pathway and autoinflamma-
tory disorders. Muckle-Wells syndrome, familial cold
autoinflammatory syndrome, and neonatal-onset multi-
system inflammatory disease are associated with consti-
tutive activation of the Nlrp3 inflammasome due to mu-
tated Nlrp3  [15] . Interestingly, a genetic study has identi-
fied single nucleotide polymorphisms likely to reduce 
Nlrp3 expression that are linked to IBD  [16] . Other au-
thors have confirmed a role for Nlrp3 in IBD, but pro-
vided evidence that a gain-of-function mutation of Nlrp3 
is associated with IBD  [17, 18] . Finally, two recent publica-
tions could not corroborate any genetic association be-
tween Nlrp3 and IBD  [19, 20] .
 These partly contradicting results from cell biology 
studies as well as human genetics studies have generated 
great interest in the role of the Nlrp3 inflammasome in 
murine models of IBD. Recently, our group reported in-
volvement of the Nlrp3 inflammasome in the pathogen-
esis of DSS-induced colitis  [8] . Peritoneal macrophages 
from Nlrp3 –/– mice treated orally with DSS showed sig-
nificantly reduced secretion of IL-1  in comparison to 
wild-type mice. Consistent with these data, colon ho-
mogenates of Nlrp3 –/– mice contained lower levels of bio-
active IL-1  and other proinflammatory cytokines. In 
addition, Nlrp3 –/– mice were less susceptible to the detri-
mental effects of oral DSS intake. Weight loss, hemato-
chezia, and histology scores, as well as mortality, were 
significantly reduced in mice lacking the Nlrp3 –/– in-
flammasome  [8] . 
 However, other groups have made opposing observa-
tions. Two recent publications found a protective effect of 
the Nlrp3 inflammasome in DSS-induced colitis  [21, 22] . 
Using bone marrow chimeras, Zaki et al.  [22] found
that Nlrp3 signaling in nonhematopoietic cells protects 
against DSS-induced colonic injury. Their study used 
higher DSS concentrations than ours (4 vs. 2%) resulting 
in faster induction of clinical symptoms. Nevertheless, in 
the study by Zaki et al.  [22] the mice showed a marked 
resistance to high DSS doses, suggesting that as yet unde-
fined factors contribute to the phenotype of Nlrp3 –/– 
mice seen in different animal facilities. 
 These contradictory results are paralleled by findings 
in caspase-1- and IL-18-deficient mice. Siegmund et al. 
 [23] reported protection of caspase-1 –/– mice from the 
deleterious effects of DSS administration and our group 
found that treatment of mice with the caspase-1 inhibitor 
pralnacasan ameliorated colonic inflammation  [24, 25] . 
In contrast, a recent study showed that caspase-1 –/– mice 
have aggravated colonic inflammation  [7] . Moreover, two 
studies found that treatment with anti-IL-18 antibody or 
IL-18-binding protein reduced the severity of DSS-in-
duced colitis  [26, 27] . In contrast, IL-18 –/– or IL-18 recep-
tor –/– mice developed a more severe colitis than wild-type 
controls, arguing for a protective role of IL-18 in tissue 
repair  [28] . As possible reasons for these opposing results, 
different DSS batches, varying DSS concentrations, and 
different mouse strains and age have been discussed. Al-
ternatively, differing intestinal microbiota in wild-type 
versus caspase-1 –/– or IL-18 –/– mice might have been a 
confounder; however, no direct evidence was available at 
that time.
 A Dual Role for the Nlrp3 Inflammasome in Epithelial 
and Mononuclear Cells 
 Despite the frequent use of the DSS-induced colitis 
model in IBD research, little is known about the precise 
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mechanisms by which DSS induces colitis in mice. Cer-
tainly, DSS is a toxin, damaging the epithelial barrier, 
which allows bacteria and microbial components to in-
teract with immune cells located in the lamina propria. 
Thus, the DSS model is generally viewed as an epithelial 
damage model suited to investigate wound-healing pro-
cesses and innate immune responses. In concordance 
with this view, clinical manifestations of DSS intake do 
not occur before the fourth or fifth day of DSS adminis-
tration, along with the appearance of histological hall-
marks of epithelial injury. 
 Other authors have suggested that DSS uptake by lam-
ina propria macrophages initiates an inflammatory pro-
cess. Araki et al. [29] noted the uptake of orally adminis-
tered DSS by lamina propria immune cells. Our own data 
also point towards a direct effect of DSS on macrophages: 
macrophages primed with LPS and subsequently exposed 
to DSS secrete high levels of IL-1  and IL-18 in an
Nlrp3-, ASC-, and caspase-1-dependent manner  [8] . This 
effect was completely abrogated when the endocytosis of 
DSS was experimentally blocked. Combining these dis-
tinct aspects of DSS action led us to postulate a two-hit 
hypothesis. First, DSS-induced epithelial damage leads to 
bacterial translocation into the lamina propria, with sub-
sequent NF-  B or cytokine receptor signaling in macro-
phages or DC, and enhanced transcription of Nlrp3, pro-
IL-1  , and pro-IL-18 (step 1). Subsequent activation of the 
Nlrp3 inflammasome by endocytosed DSS induces the 
cleavage of cytokines into their biologically active forms 
and their subsequent secretion, initiating and entertain-
ing an inflammatory cascade (step 2;  fig.  1 ). However, 
other yet to be defined mechanisms in vivo may lead to 
IL-1  and IL-18 processing independent of the Nlrp3 in-
flammasome. 
 Role for the Nlrp3 Inflammasome in the
TNBS-Induced Colitis Model 
 We previously reported that weight loss, hematoche-
zia, and histology scores, as well as mortality, are signifi-
cantly reduced in mice lacking the Nlrp3 inflammasome 
in the acute DSS colitis model  [8] . As mentioned before, 
a putative direct effect of DSS on Nlrp3 inflammasome 
activation in macrophages and DC has to be considered 
when trying to understand the exact pathophysiological 
role of Nlrp3 in IBD. We therefore examined a second 
model of chemically-induced colitis, the TNBS model, in 
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 Fig. 1. Proposed pathophysiological model 
of DSS-induced colitis. The integrity of in-
testinal epithelial cells (IEC) is disrupted 
by direct toxic effects of DSS, allowing 
bacteria and DSS particles to get into con-
tact with macrophages and DC located in 
the lamina propria. Bacterial compounds 
induce NF-  B or cytokine receptor signal-
ing with transcriptional upregulation of 
Nlrp3, pro-IL-1  , and pro-IL-18 (step 1 of 
the proposed two-hit theory of DSS action, 
see text). Uptake of DSS into macrophages 
and DC activates the Nlrp3 inflamma-
some, resulting in activation of caspase-1, 
which in turn cleaves pro-IL-1  and pro-
IL-18 into the biologically active forms 
(step 2). Proinflammatory cytokines, such 
as IL-12 and IL-18, induce the activation 
and differentiation of CD4+ T cells into a 
Th1 phenotype, entertaining the inflam-
matory response. In contrast, release of IL-
18 from IEC may be an important regula-
tory mechanism, promoting mucosal re-
pair after DSS-induced damage. 
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which suspension of TNBS in ethanol is administered 
rectally. TNBS can cross the mucosal barrier and has 
been described as a T cell-driven model, presumably by 
acting as a hapten to activate T cells directly. However, 
bystander mononuclear cells also appear to be involved 
in the TNBS-induced immune response  [30–32] . After 
rectal application of TNBS, mice developed severe intes-
tinal inflammation and weight loss within a few days. As 
observed in the DSS model, clinical disease severity, as 
assessed by diarrhea, bloody stools, weight loss, and mor-
tality, was significantly reduced in Nlrp3 –/– mice, indicat-
ing that Nlrp3-deficiency may also protect against TNBS 
challenge ( fig. 2 ). 
 Effects of Inflammasome-Deficiency on the 
Composition of Intestinal Microflora  
 The key for understanding the apparently discrepant 
results of colitis experiments performed in different lab-
oratories may be found in environmental factors, such 
as the intestinal microbiota, that can vary between dif-
ferent facilities and mouse strains  [33] . Flavell’s group 
 [7] has established an elegant model to investigate the 
role of the intestinal microflora in DSS-induced colitis 
in inflammasome-deficient mice. ASC –/– and Nlrp6 –/– 
mice exhibited a higher susceptibility to DSS-induced 
colitis when compared to wild-type mice. However, co-
housed wild-type and ASC –/– or Nlrp6 –/– mouse strains 
were similarly susceptible to DSS challenge, indicating 
that a ‘colitogenic’ intestinal flora can be transferred 
from one strain to the other. Analysis of the fecal micro-
biota of Nlrp6 –/– , ASC –/– , caspase-1 –/– , and IL-18 –/– mice 
versus wild-type mice by 16S rRNA-based analysis re-
vealed a higher frequency of Prevotellaceae, which be-
long to the phylum Bacteroidetes, in mice lacking the 
respective components of the inflammasome cascade. 
Interestingly, abrogation of Prevotellaceae by antibiotics 
rendered Nlrp6 –/– mice as sensitive to DSS as wild-type 
mice. The authors concluded from their observations 
that the differences in DSS susceptibility of wild-type 
and inflammasome-deficient mice seen by different lab-
oratories might be explained by a specific composition 
of the intestinal microbiota. In support of this idea is a 
recently published study, which described a specific role 
for microbiota in inflammasome-deficient animals in 
nonalcoholic fatty liver disease and obesity  [34] . Thus, 
interactions between genotype and environmental fac-
tors add another level of complexity to IBD that had un-
til now escaped attention in experimental IBD mouse 
studies. 
 These exciting data led us to investigate the influence 
of cohousing wild-type and Nlrp3 –/– mice in the acute 
DSS colitis model. To assure transfer of intestinal micro-
biota, both mouse strains were kept together in cages for 
2 weeks before receiving 2% DSS in drinking water. Un-
der these conditions both mouse strains lost weight to the 
same extent and developed a similar severity of hemato-
chezia, indicating that the susceptibility of wild-type 
mice towards DSS was transmittable to Nlrp3 –/– mice. 
Also, histological analyses of the distal colon showed al-
most identical inflammatory reactions in the two mouse 
strains ( fig. 3 a). In addition, treatment of the mice with a 
combination of four antibiotics almost completely pre-
vented the detrimental effects of DSS exposure in both 
mouse strains ( fig. 3 b). From these findings and reports 
in the literature  [35, 36] we conclude that gut microbiota 
are critical determinants for the severity of DSS-induced 
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colitis and that the influence of genetic factors on the in-
testinal microbiota has to be considered when comparing 
knockout mice with wild-type mice in experimental coli-
tis models. 
 DC in the Lamina Propria of Nlrp3-Deficient Mice 
Express a Tolerogenic Phenotype 
 What further steps are necessary to clarify the role of 
Nlrp3 in IBD models? The importance of diverse cell 
types involved in antigen sampling and presentation in 
the lamina propria in the regulation of the homeostasis 
of the gut immune system has been appreciated  [37] . The 
precise roles of macrophages and DC in DSS-induced 
colitis are a matter of ongoing debate, as both proinflam-
matory and anti-inflammatory effects have been de-
scribed. Depletion of macrophages/DC with liposome-
encapsulated clodronate ameliorated colitis in IL-10-
deficient mice, indicating that intestinal mononuclear 
phagocytes play a proinflammatory role  [38] . In turn, se-
lective depletion of CD11c+ DC aggravated DSS-induced 
colitis, indicating that DC may be protective, e.g. via se-
cretion of anti-inflammatory cytokines such as IL-10 or 
TGF-   [39] . Recently, CD103+ DC have been described 
as potent inductors of regulatory T cells in murine colitis 
models  [40] . These tolerogenic DC are believed to repre-
sent a mucosal phenotype of DC characterized by upreg-
ulation of CD103 upon arrival of monocytic precursors 
from the blood in the intestine and differentiation into 
DC  [41, 42] . 
 The factors that contribute to the tolerogenic environ-
ment in the gut are largely unknown, but might putative-
ly include retinoic acid and TGF-  produced by intestinal 
epithelial cells and/or immune cells in the lamina propria 
 [43] . The tolerogenic potential of CD103+ DC appears to 
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be restricted to the steady state  [44] , while during intesti-
nal inflammation this tolerogenic function appears to be 
lost  [45] . Apparently, an imbalance of the various lamina 
propria DC subpopulations predisposes to IBD develop-
ment  [37, 46] . The question remains, which mechanisms 
guide the transition from steady state to a proinflamma-
tory state in the gastrointestinal tract?
 As Nlrp3 –/– mice were protected against DSS- and 
TNBS-induced colitis, specifically in the early phase of 
the disease, we speculated that lamina propria DC of 
Nlrp3 –/– mice might express a more tolerogenic pheno-
type under steady state conditions. To address this ques-
tion, we generated single cell suspensions from lym-
phatic organs and the lamina propria of wild-type and 
Nlrp3 –/– mice and stained these with fluorochrome-
labeled antibodies against CD11b, CD11c, CD86, and 
CD103 for analysis by flow cytometry. In lymphatic or-
gans as well as in the lamina propria, CD11b+CD11c+ DC 
demonstrated CD103– and CD103+ subpopulations. We 
found that the frequency of CD103+ DC amongst all 
CD11b+CD11c+ cells derived from the lamina propria 
was significantly higher in Nlrp3 –/– mice than in wild-
type mice ( fig. 4 a). Similarly, CD103+ DC were more fre-
quent among CD11b+CD11c+ cells from the spleens of 
Nlrp3 –/– mice than from wild-type mice (22.7  8 1.1% vs. 
10.0  8 2.1%, p  ! 0.001). We also noted that the total
number of CD11b+CD11c+ DC did not differ between
Nlrp3 –/– and wild-type mice. Finally, expression of the 
costimulatory molecule CD86 was found to be reduced 
on CD103+ DC derived from the spleens of Nlrp3 –/– mice 
( fig. 4 b). No difference in CD86 expression was observed 
for CD103– DC (data not shown).
 These findings confirm that lamina propria DC in 
Nlrp3 –/– mice express a more tolerogenic phenotype, 
which may account for the reduced susceptibility in 
chemically induced colitis models. The precise role of the 
tolerogenic phenotype of lamina propria DC in Nlrp3 –/– 
mice in steady state and in inflammatory conditions is 
the focus of ongoing studies in our laboratory.
 Conclusion 
 Inflammasome- and caspase-1-regulated processes 
play a pivotal role in intestinal homeostasis and inflam-
mation. Both protective and detrimental effects of the 
Nlrp3 inflammasome and IL-18 have been described in 
murine IBD models. A possible key is compartmentaliza-
tion of IL-18 processing. While epithelial cell-derived IL-
18 might exert a protective effect by assuring the mainte-
nance of mucosal integrity, IL-18 produced by lamina pro-
pria immune cells, such as macrophages or DC, can 
trigger a proinflammatory cascade and, hence, contribute 
to excessive tissue damage in predisposed individuals. 
However, recent studies have added another layer of com-
plexity. Genetic alterations in components of inflamma-
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steady state.  a Single cell suspensions of lamina propria cells were 
stained with fluorochrome-labeled antibodies and analyzed by 
flow cytometry. No difference in the total number of CD11c+ DCs 
was observed between Nlrp3 –/– mice and wild-type mice (not 
shown); Nlrp3 –/– mice exhibited a higher frequency of CD103+ 
CD11c+ DC compared to wild-type mice (24.7  8 8.8 vs. 14.9  8 
3.2%).  b The frequency of splenic CD103+ CD11+ DC was in-
creased in Nlrp3 –/– mice, whereas the expression of the costimula-
tory molecule CD86 was significantly reduced, indicative of a 
tolerogenic DC phenotype. Shown are data from one of two inde-
pendent experiments with 5 mice per group. Data in  b are indi-
vidual measurements, as well as mean values  8 SEM of 5 mice.
 * p  ! 0.05. 
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